In this study, we report the serial passaging of the original NT2.5 cell line to generate a new subline called NT2.5-LM, which represents an orthotopic, immunotolerant model of HER2+ breast cancer capable of promoting development of spontaneous metastases. Here, ERBB2 is linked to breast cancer.